With few exceptions, testicular cancer is characterized by malignant tumours which typically arise from germ cells. It is one of the most common cancers in young men, the peak age is between 20 and 40 years of age. Testicular cancer, with four to eight diseases per 100,000 men, is rare compared to other cancers. It accounts for only one to two percent of all malignant tumours.
The leading symptom of a testicular tumour is the slowly emerging, painless swelling of a testicle, with a palpable nodule formation within the testis. The patient becomes aware of this because of a heavy feeling of the testicle. Potency problems and an enlargement of the breast (gynecomastia) can be evidence of testicular cancer. Malignant testicular tumours often metastasise in the nearby lymph nodes, but also through the bloodstream in the skeleton, liver and lung.
During an examination, the tumour is palpable as a firm, usually pressure-painless lump. Further diagnostics used are a testicular ultrasound, and a blood test focusing on specific tumour markers. The computer tomography, Urography and Lymphography, and also an X-ray of the chest, provide additional diagnostic options.
All men should self-check their testicles once a month from adolescence onwards, preferably in a warm environment as the scrotal skin relaxes, and changes are easier to detect.
Recommended therapies for the treatment of testicular cancer:
Whole body Hyperthermia
For patients with testicular cancer the healing effect of whole-body hyperthermia is that we can very quickly bring the body to high temperatures (up 40.5 °). This fast and high heating activates not only the immune system, but many degenerate germ cells are destroyed by the fast floods of heat. In addition to the damage or removal of the cancer cells, the whole-body hyperthermia stimulates the immune system enormously without impacting the rest of the body. It triggers an immune cascade that activates and multiplies the white blood cells.
IPT- Low Dose Chemotherapy
Patients with testicular cancer can be successfully treated at the Hyperthermia Centre Hannover with the IPT, which uses the blood sugar-lowering hormone to better transport drugs such as chemotherapeutic agents into tumor cells. Since the degenerated cells of the testicular carcinoma have a higher basal metabolic rate than normal body cells, they are anxious to absorb sugar more quickly after a period of hypoglycaemia. The mechanism takes place via so-called receptors. Since tumor cells in the testes have more receptors than normal body cells, chemotherapy can thus act more effectively on the malignant cells. As a result, the dosage of common chemotherapy protocols can be significantly reduced and thus the side effects are significantly lowered.